Gene-Editing Company, GeneTether, Announces New Location at MBC BioLabs San Francisco and Upcoming Company Presentations

USA - English

• USA - English

SAN FRANCISCO, Nov. 10, 2018 /PRNewswire-PRWeb/ -- GeneTether, a gene-editing company, announces that it has moved its operations to new laboratory space at MBC BioLabs in San Francisco after having been selected by MBC BioLabs, a well known San Francisco Bay Area incubator, as a new resident company.

"I am pleased to announce our collaboration with MBC BioLabs." stated Geoff Sargent, PhD, CEO of GeneTether. " It has with a very well equipped lab and other facilities to accelerate our growth. But, most importantly, I am finding that the talent and energy of fellow scientist/entrepreneurs stimulates our mind-set and energizes our creative process."

Dr. Sargent will be a speaker in a panel discussion on gene editing at the CEO Life Sciences & Pharmaceuticals Symposium hosted by YJP on November 13-14, 2018 in New York City.

GeneTether will also be hosting a "meet and greet" at its new space at MBC Biolabs on November 28, 2018. Parties interested in attending this event should contact GeneTether below.

Contact
Geoff Sargent
510-207-2046
geoff(at)genetether.com

About GeneTether
GeneTether's initial patent-pending technology is focused on improving the efficiency of CRISPR, TALENS, and Zinc Finger Nucleases by a factor of at least 10x while reducing unwanted DNA mutation. Longer term, GeneTether plans to develop its technology by eliminating genetic defects in large farm animals, such as pigs and cattle. This will pave the way for correcting genetic defects in human cells.

About MBC BioLabs
MBC BioLabs provides space as small as a single bench in fully-equipped labs. Scientists can conduct experiments on their first day, cutting months and millions of dollars off the time and cost necessary to gather data. MBC BioLabs facilities in San Francisco and San Carlos are home to 61 energetic young companies. Since opening its doors five years ago, MBC BioLabs tenant companies have raised over $2.4 billion dollars. http://www.mbcbiolabs.com

About the CEO Life Sciences & Pharmaceuticals Symposium and YJP
This annual symposium convenes a group of industry-leading executives, researchers, entrepreneurs and investors to explore solutions to the most pressing problems surrounding the research and development process - such as reducing the time and cost of drug development, drug pricing, raising capital, and more - while celebrating the advancements currently being made and encouraging the life sciences leaders of tomorrow. This symposium will be a unique opportunity to candidly share knowledge and engage in innovative solutions that will stimulate positive change within the life sciences industry. YJP is a not-for-profit organization focused on providing business, educational, and mentoring opportunities for the new generation of Jewish business leaders.

About Gene Editing
Gene editing (also called genome editing) is a group of technologies (CRISPR/Cas; TALENS; and ZFNs) that enable scientists to change an organism's DNA. These technologies allow genetic material to be added, removed, or altered at particular locations in the genome and work by creating site-specific DNA strand breaks to increase the frequency of gene editing. CRISPR gene editing is modeled after the way that certain bacteria naturally alter genes in response to viruses and other organisms. Many scientists believe CRISPR/Cas systems offer significant advantages over preceding gene editing technologies, such as Zinc-Finger Nucleases (ZFNs) and Transcription Activator-Like Effector Nucleases (TALENs) because they are more easily modified to recognize.

SOURCE GeneTether